These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18355384)

  • 1. Testing and estimation of time-varying cause-specific hazard ratios with covariate adjustment.
    Sun Y; Hyun S; Gilbert P
    Biometrics; 2008 Dec; 64(4):1070-9. PubMed ID: 18355384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.
    Gilbert PB
    Stat Med; 2000 Nov; 19(22):3065-86. PubMed ID: 11113943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
    Juraska M; Gilbert PB
    Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.
    Gilbert P; Self S; Rao M; Naficy A; Clemens J
    J Clin Epidemiol; 2001 Jan; 54(1):68-85. PubMed ID: 11165470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.
    Durham LK; Longini IM; Halloran ME; Clemens JD; Nizam A; Rao M
    Am J Epidemiol; 1998 May; 147(10):948-59. PubMed ID: 9596473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
    Gilbert PB; McKeague IW; Sun Y
    Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.
    Sun Y; Gilbert PB; McKeague IW
    Ann Stat; 2009 Feb; 37(1):394-426. PubMed ID: 19838313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
    Sun Y; Li M; Gilbert PB
    Biostatistics; 2013 Jan; 14(1):60-74. PubMed ID: 22764174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.
    Li Z; Gilbert P; Nan B
    Biometrics; 2008 Dec; 64(4):1247-55. PubMed ID: 19032178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated.
    Follmann D; Fay M; Magaret C
    Stat Med; 2022 Jul; 41(16):3076-3089. PubMed ID: 35396728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.
    Dai JY; Li SS; Gilbert PB
    Biostatistics; 2014 Jan; 15(1):196-203. PubMed ID: 23813283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model selection for Cox models with time-varying coefficients.
    Yan J; Huang J
    Biometrics; 2012 Jun; 68(2):419-28. PubMed ID: 22506825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sieve analysis using the number of infecting pathogens.
    Follmann D; Huang CY
    Biometrics; 2018 Sep; 74(3):1023-1033. PubMed ID: 29238965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the relation between the cause-specific hazard and the subdistribution rate for competing risks data: The Fine-Gray model revisited.
    Putter H; Schumacher M; van Houwelingen HC
    Biom J; 2020 May; 62(3):790-807. PubMed ID: 32128860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimability and interpretation of vaccine efficacy using frailty mixing models.
    Halloran ME; Longini IM; Struchiner CJ
    Am J Epidemiol; 1996 Jul; 144(1):83-97. PubMed ID: 8659489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying time-varying cause-specific hazard and subdistribution hazard ratios with competing risks data.
    Diao G; Ibrahim JG
    Clin Trials; 2019 Aug; 16(4):363-374. PubMed ID: 31165631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causes.
    Heng F; Sun Y; Hyun S; Gilbert PB
    Lifetime Data Anal; 2020 Oct; 26(4):731-760. PubMed ID: 32274677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying the Cox proportional hazards model when the change time of a binary time-varying covariate is interval censored.
    Goggins WB; Finkelstein DM; Zaslavsky AM
    Biometrics; 1999 Jun; 55(2):445-51. PubMed ID: 11318198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials.
    Sun Y; Qi L; Yang G; Gilbert PB
    Biom J; 2018 May; 60(3):516-536. PubMed ID: 29488249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.